Benjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 1,000 shares of the business's stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $22.52, for a total value of $22,520.00. Following the completion of the sale, the chief financial officer now directly owns 13,000 shares of the company's stock, valued at $292,760. The trade was a 7.14 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Monday, January 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.59, for a total value of $70,167.50.
• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.04, for a total transaction of $25,040.00.
• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.51, for a total transaction of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.15, for a total transaction of $74,202.50.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.89, for a total transaction of $130,672.50.

Enliven Therapeutics Trading Down 0.7 %

Shares of ELVN stock traded down $0.15 during trading on Tuesday, hitting $21.40. The company's stock had a trading volume of 77,354 shares, compared to its average volume of 243,825. The company has a market cap of $1.05 billion, a PE ratio of -11.25 and a beta of 1.03. The business has a fifty day moving average of $22.77 and a 200-day moving average of $24.23. Enliven Therapeutics, Inc. has a 52 week low of $10.90 and a 52 week high of $30.03.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ELVN shares. BTIG Research assumed coverage on Enliven Therapeutics in a research note on Friday, December 13th. They issued a "buy" rating and a $42.00 price objective for the company. Robert W. Baird increased their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the company an "outperform" rating in a research report on Friday, November 15th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $38.25.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. KLP Kapitalforvaltning AS purchased a new position in shares of Enliven Therapeutics in the fourth quarter valued at $97,000. China Universal Asset Management Co. Ltd. lifted its stake in Enliven Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company's stock worth $232,000 after purchasing an additional 3,559 shares in the last quarter. SG Americas Securities LLC bought a new position in Enliven Therapeutics in the 3rd quarter valued at $256,000. Verition Fund Management LLC purchased a new position in shares of Enliven Therapeutics during the 3rd quarter valued at $271,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Enliven Therapeutics in the second quarter worth $322,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.